Xenon Pharmaceuticals Inc. XENE
37.75 USD -1.03 (-2.66%)
Regular-session close
37.75 0.00 0.00%
After hours · Nov 18, 5:20 PM ET
37.65 Day range 39.72
33.49 52-week range 70.96
- YTD
- -15.77%
- 1 year
- -7.04%
News
benzinga.com JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Lowers Price Target to $80 JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and lowers the price target from $82 to $80.
zacks.com Xenon Stock Rises 12% in the Past Month on Pipeline Progress XENE's shares jump 12% as azetukalner advances, pain candidates deliver encouraging results and a strong cash position supports pipeline growth.
seekingalpha.com Xenon Pharmaceuticals Inc. (XENE) Q3 2026 Earnings Call Transcript Xenon Pharmaceuticals Inc. (XENE) Q3 2026 Earnings Call Transcript
marketbeat.com Xenon Pharmaceuticals Q3 Earnings Call Highlights Xenon Pharmaceuticals NASDAQ: XENE expects pivotal depression study results in December, earlier than previously projected, while preparing for a potential U.S. launch of its lead epilepsy drug and…
benzinga.com Xenon Pharmaceuticals Q3 2026 Earnings Call Transcript Xenon Pharmaceuticals (NASDAQ:XENE) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Xenon Pharmaceuticals Q3 EPS $(1.11) Beats $(1.13) Estimate Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(1.11) per share which beat the analyst consensus estimate of $(1.13) by 1.77 percent. This is a 3.48 percent increase over losses of…
globenewswire.com Xenon Reports Q3 2026 Financial Results and Provides Business Update New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026 Expanding potential opportunity in epilepsy through ongoing Phase 3 X-TOLE3 and…
globenewswire.com Xenon to Present at Upcoming Investor Conferences VANCOUVER, BC and BOSTON, MA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical…
globenewswire.com Xenon to Report Q3 2026 Financial Results on November 9, 2026 VANCOUVER, BC and BOSTON, MA, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical…
globenewswire.com Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VANCOUVER, BC and BOSTON, MA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical…benzinga.com Xenon Pharmaceuticals Announces Its XEN1701 Surpasses Target Profile; Data Presented During International Association For The Study Of Pain 2026 World Congress On Pain Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for…
globenewswire.com Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain XEN1701 achieved target profile, including desired Na V 1.7 receptor occupancy in both the peripheral and central nervous system, and was generally well-tolerated with no notable autonomic…
globenewswire.com Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is continuing its investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ:…
zacks.com XENE's Depression Trial Setback: Is Its Pipeline Still Attractive? Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.
globenewswire.com Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP continues to investigate potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).
globenewswire.com Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical…
newsfilecorp.com Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company…
marketbeat.com Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review Xenon Pharmaceuticals NASDAQ: XENE said it has filed its first new drug application for azetukalner as a treatment for focal-onset seizures, while pausing portions of its late-stage psychiatry…
businesswire.com XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $XENE--XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law.
prnewswire.com Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE) Analysts cut price targets and reduced their estimates for azetukalner's psychiatric commercial opportunity after Xenon Pharmaceuticals disclosed an enrollment pause in its Phase 3 depression trials…
seekingalpha.com Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate Azetukalner's focal-seizure application gives Xenon Pharmaceuticals Inc. a potential path to its first commercial revenues, subject to FDA approval. The psychiatry setback weakens expansion…
globenewswire.com Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).
globenewswire.com Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical…
proactiveinvestors.com Xenon Pharmaceuticals falls 30% after depression trial enrollment pause Xenon Pharmaceuticals Inc. (XENE:NASDAQ) shares were down 30%, on Friday morning after the company voluntarily halted new enrollment in major depressive disorder and bipolar depression studies. The…
